Strategic divestment Gerresheimer is actively restructuring its portfolio, evidenced by the sale of two packaging units to Apax for around €1.5 billion. This signals potential opportunities to position high-value packaging, drug delivery, and digital solutions to a management team focused on core assets and optimization, especially in areas where non-core units were previously handled internally.

Cash preservation Recent earnings commentary highlight a priority on cash preservation, reduced capital expenditure, and controlled inventory buildup. This creates openings for offerings that improve cash efficiency, such as flexible supply chain services, value-engineered packaging solutions, and cost-effective digital platforms that minimize working capital requirements.

Debt refinancing Management focus on refinancing debt and improving cash generation suggests receptivity to financial products or bundled supplier-financing arrangements, as well as scalable packaging and device solutions that deliver predictable cost-of-goods-sold and working-capital benefits.

Digital leadership The tech footprint includes Databricks, Snowflake, Kubernetes, and digital solutions, indicating a maturity in data-driven operations. Sales opportunities exist for advanced analytics services, manufacturing intelligence, and digital patient-centric delivery systems that can be integrated with existing platforms to optimize quality, traceability, and customization.

Global, local focus With over 40 production sites across 16 countries and a strategy to produce locally for regional markets, Gerresheimer seeks scalable, regionally tailored packaging and device solutions. This presents opportunities for localized manufacturing partnerships, faster time-to-market programs, and regulatory-compliant packaging variants for key regional markets.